DataMeds AI, Inc.MEDS
Price (close)
$3.50
Market cap
—
P/E
—
Revenue (TTM)
$8.0M
Net income
-$88.3M
Dividend yield
—
1-year total return
-93.1%
Net margin
-1100.3%
Revenue growth
-78.2%
Debt / equity
—
What DataMeds AI, Inc. does.
in 2022, we are a holding company for existing and future planned operating companies centered around pharmaceuticals and healthcare
services. We seek to be a micro health ecosystem, with a portfolio of companies consisting of a pharmacy, wholesale operations, and a
technology division that provides a novel platform for hub and clinical services. We are focused on improving the lives of patients while
Revenue and profit, by fiscal year.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | — | — | $18.1M | $23.3M |
| Net income | — | -$2.9M | -$6.9M | -$101.3M |
More on MEDS.
- DataMeds AI, Inc. summary
- DataMeds AI, Inc. financial statements
- DataMeds AI, Inc. key metrics
- DataMeds AI, Inc. health scores and style box
- DataMeds AI, Inc. earnings
- DataMeds AI, Inc. dividends
- DataMeds AI, Inc. valuation
- DataMeds AI, Inc. ownership and insiders
- DataMeds AI, Inc. peers
Figures from DataMeds AI, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.